US 12,708,663

Application 18/036,631 · Granted Aug 18, 2026

Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain

Estimated expiration

July 3, 2043

16y 227d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Nov 17, 2021
+ 20 years
Nov 17, 2041
PTA +593d
Jul 3, 2043
No TD
—
Final
Jul 3, 2043

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
May 11, 2023
Earliest effective filing
November 17, 2021
Issue date
August 18, 2026
PTA
+593 days
Base expiry (before PTA)
November 17, 2041

November 17, 2021 + 20 years = November 17, 2041 + 593 PTA days = July 3, 2043

  • National stage entry of application PCTUS2021059788, filed Nov 17, 2021
  • PRO63/114,941 — Provisional — not used for base term
  • PRO63/114,941 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 18/036,631 · US 12,708,663

PatentReply compiles the prosecution history behind US 12,708,663: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12708663

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.